Please assess the completion status of the following clinical trial:

Trial Title: Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosis of chronic atopic dermatitis (AD) for at least 6 months~* Moderate to severe AD (BSA at least 10%, IGA at least 3, EASI at least 16, and PP-NRS severity score at least 4)~* Recent history of inadequate response to treatment with medicated topical therapy for AD, or who have required systemic therapies for control of their disease~Exclusion Criteria:~* Acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation~* Have increased risk of developing venous thromboembolism~* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study~* Prior treatment with systemic JAK inhibitors or IL-4 or IL-13 antagonists including dupilumab, lebrikizumab or tralokinumab~* Other active non-AD inflammatory skin diseases or conditions affecting skin~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, malignancies, current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator~* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abrocitinib 200 mg plus placebo injection (Type: EXPERIMENTAL): Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
- Dupilumab 300 mg plus placebo tablets (Type: ACTIVE_COMPARATOR): Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26

Based on this trial design, predict the completion outcome and termination type (if applicable).